One of the major patient benefits of SGLT2 inhibition is that blood glucose levels are reduced without increasing the risk of hypoglycemia or producing weight gain, both of which are major and unpreventable side effects of other classes of oral anti-hyperglycemic drugs. Here, SLC5A2 is linked to Hypoglycemia.